A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Trial Profile

A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Suspended
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Crizotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
  • Indications Anaplastic large cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to suspended.
    • 14 Sep 2015 Drug intake time has changed in treatment: COURSE A (COURSES 1, 3, AND 5): cytarabine IV over 1 hour every 12 hours to cytarabine IV over 1-30 minutes every 12 hours. COURSE B (COURSES 2, 4, AND 6): cyclophosphamide IV over 30-60 minutes on days 1-5 to cyclophosphamide IV over 15-30 minutes on days 1-5, as reported by ClinicalTrials.gov record.
    • 28 Oct 2014 New source identified and integrated (Vanderbilt Ingram Cancer Center - COGANHL12P1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top